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Objective: Transfemoral carotid artery stenting (CAS), with or without distal protection, is associated with risk for
cerebral and peripheral embolism and access site complications. To establish cerebral protection before crossing the
carotid lesion and to avert transfemoral access complications, the present study was undertaken to evaluate a transcervical
approach for CAS with carotid flow reversal for cerebral protection.
Methods: Fifty patients underwent CAS through a transcervical approach. All patients with symptoms had greater than
60% internal carotid artery (ICA) stenosis, and all patients without symptoms had greater than 80% ICA stenosis.
Twenty-one patients (42%) had symptomatic disease or ipsilateral stroke, and 8 patients (16%) had contralateral stroke.
Four patients (8%) had recurrent stenosis, 7 patients (14%) had contralateral ICA occlusion, and 1 patient (2%) had
undergone previous neck radiation. Twenty-seven procedures (54%) were performed with local anesthesia, and 23 (46%)
with general anesthesia. Using a cervical cutdown, flow was reversed in the ICA by occluding the common carotid artery
and establishing a carotid–jugular vein fistula. Pre-dilation was selective, and 8-mm to 10-mm self-expanding stents were
deployed and post-dilated with 5-mm to 6-mm balloons in all cases.
Results: The procedure was technically successful in all patients, without significant residual stenoses. No strokes or deaths
occurred. There was 1 wound complication (2%). All patients were discharged within 2 days of surgery. Mean flow
reversal time was 21.4 minutes (range, 9-50 minutes). Carotid flow reversal was not tolerated in 2 patients (4%). Early in
the experience, carotid flow reversal was not possible in 1 patient, and there were 1 major and 3 minor common carotid
artery dissections, which resolved after stent placement. One intraoperative transient ischemic attack (2%) occurred in 1
patient in whom carotid flow was not reversed, and 1 patient with a contralateral ICA occlusion had a contralateral
transient ischemic attack. At 1 to 12 months of follow-up, all patients remained asymptomatic, and all but 1 stent
remained patent.
Conclusion: Transcervical CAS with carotid flow reversal is feasible and safe. It can be done with the patient under local
anesthesia, averts the complications of the transfemoral approach, and eliminates the increased complexity and cost of
cerebral protection devices. Transcervical CAS is feasible when the transfemoral route is impossible or contraindicated,
and may be the procedure of choice in a subset of patients in whom carotid stenting is indicated. (J Vasc Surg 2004;40:
476-83.)The beneficial effect of cerebral protection during ca-
rotid artery stenting (CAS) has not been proved in con-
trolled, prospective trials. It is well established, however,
that cerebral embolization is a common event that occurs
almost universally during all technical steps of CAS1,2 and
that a large number of microembolic signals are detected
with transcranial Doppler scanning during CAS.3 Embolic
protection during CAS has not been universally accepted,
because of the relatively low incidence of clinically apparent
stroke during CAS and lack of correlation of embolic
signals with clinically significant neurologic events. How-
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doi:10.1016/j.jvs.2004.06.026476ever, a meta-analysis of multiple institutional experiences
has suggested that cerebral protection during CAS may be
associated with reduction in the incidence of cerebral em-
bolization and neurologic complications.4 The Safety
Committee of the European Endarterectomy Versus An-
gioplasty in Patients With Symptomatic Severe Carotid
Stenosis trial, which compared CAS with or without cere-
bral protection with carotid surgery in patients with re-
cently symptomatic, severe carotid artery stenosis, has re-
cently recommended limiting the trial to patients with
protection during CAS, because of a 3.9-fold higher inci-
dence of stroke in CAS without protection.5 Although the
data are not based on a randomized comparison of unpro-
tected versus protected CAS, they suggest that cerebral
protection during CAS reduces the incidence of stroke.
This evidence reinforces the preexisting consensus on
the advisability of the use of cerebral protection during
CAS.6 Currently available cerebral protection devices,
however, provide incomplete protection, and their use adds
significantly to the complexity, duration, and cost of CAS.7
Distal protection devices (DPDs) currently under clinical
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and potential complications.8 Distal balloon occlusion de-
vices reduce only partially the incidence of periprocedural
embolization during CAS,9,10 and distal filtering devices
fail to capture a significant number of embolic particles
released during CAS both in vitro11 and in vivo.12,13 In
addition, all distal protection systems require crossing the
carotid lesion before protection is in place, arguably one of
the most emboligenic maneuvers during CAS.
Cerebral protection with proximal common carotid
artery (CCA) occlusion and internal carotid artery (ICA)
flow reversal suppresses cerebral embolization in vitro,14
and produces a negligible incidence of periprocedural neu-
roembolic complications in vivo.15,16 The transfemoral
approach for CAS, with or without protection, is associated
with a small but definite risk for cerebral and peripheral
embolization secondary to arch and proximal supra-aortic
trunk instrumentation, and groin complications. In addi-
tion, the transfemoral route may not be feasible in patients
with severe aortoiliac occlusive disease or in patients with
unfavorable anatomy.
To incorporate the advantages of cerebral protection
with ICA flow reversal and to eliminate the potential com-
plications, increased technical complexity, and additional
cost of transfemoral protection devices, we developed a
technique that uses a transcervical approach with ICA flow
reversal.17 The purpose of the present study was to evaluate
the results of this technique in our first 50 patients.
METHODS
Patients. From March 2003 to March 2004, 50 con-
secutive patients underwent transcervical CAS. Ten of these
patients were part of a separate prospective study to evalu-
ate changes in cerebral venous oxygen saturation during
transcervical CAS, and are the base of another report.18
Data were prospectively collected regarding medical his-
tory, comorbid conditions, symptomatic status, degree of
carotid stenosis, intraoperative findings and events, and
postoperative follow-up.
Patient mean age was 71.6 years (range, 57-84 years).
Forty-two patients (84%) were men. Associated medical
comorbid conditions are summarized in the Table. The
indications for CAS were high cardiac risk in 22 patients, in
10 of them before coronary revascularization, severe
chronic obstructive pulmonary disease in 3 patients, recur-
rent carotid stenosis after endarterectomy in 4 patients,
high bifurcation in 4 patients, high ICA lesion in 3 patients,
unfavorable neck anatomy in 2 patients, and neck radiation
in 1 patient. In 11 cases the decision was made by surgeon
and patient consensus, after all treatment alternatives had
been presented to the patients. Informed consent of the
off-label use of stents was obtained from all patients. The
procedures were conducted at national health care systems
where no third parties were billed for hospital or physician
services.
Twenty-one patients (42%) had symptomatic carotid
artery stenosis, 14 with hemispheric transient ischemic
attack (TIA), 1 with amaurosis fugax, and 6 with a previousipsilateral hemispheric stroke. In addition, 8 patients (16%)
had previous contralateral hemispheric stroke. Seven pa-
tients had occlusion of the contralateral ICA, and 2 patients
had occlusion of the ipsilateral external carotid artery
(ECA). Four patients had recurrent ICA stenosis after
carotid endarterectomy, and in 2 patients the lesion was
located in the distal ICA and deemed too high for safe
surgical access. The treated carotid artery was the right in
29 patients (58%), the left in 19 patients (38%), and both in
1 patient (2%).
The degree of carotid artery stenosis was estimated
preoperatively with duplex ultrasound scanning in all pa-
tients. Preoperative carotid angiography was performed in
27 patients (54%). North American Symptomatic Carotid
Endarterectomy Trial criteria were used to assess the angio-
graphic degree of stenosis. Intraoperative anteriography
with portable fluoroscopy confirmed the degree of carotid
stenosis in all patients.
Transcervical CAS protocol and technique. All pa-
tients received aspirin, 325 mg/day, and clopidogrel, 75
mg once a day, for at least 4 days, or 300 mg/day for 2 days
before the procedure. Twenty-seven procedures (54%)
were performed with local anesthesia, mostly in patients at
high cardiac risk, and 23 procedures (46%) were performed
with general anesthesia in patients without cardiac contra-
indications. Two procedures were initiated with local anes-
thesia and converted to general anesthesia because of pa-
tient discomfort. No sedation was given before or during
the procedure in patients under local anesthesia. One hun-
dred units of heparin per kilogram of body weight was
given intravenously before carotid puncture. Intra-arterial
blood pressure and transcutaneous oxygen saturation were
continuously monitored in all patients. In procedures per-
formed in patients under local anesthesia, neurologic status
was assessed at regular intervals by the anesthesiologist and
surgeon.
A description of our surgical technique for transcervical
carotid angioplasty and stenting has been published.17 The
technique consists of accessing the CCA through a vertical
mini-incision (4 cm) at the base of the neck, controlling the
proximal CCA with a Rummel loop, and establishing an
arteriovenous fistula between the CCA and the internal
jugular vein by placing 8F  11-cm introducer sheaths
(Super Arrow Flex percutaneous introducer sheath; Arrow
International) in these vessels and connecting the introduc-
ers with a short (15 cm) segment of tubing. After occluding
Medical comorbid conditions in 50 patients undergoing
transcervical carotid artery surgery
Medical comorbid condition n %
Hypertension 42 84
Hypercholesterolemia 25 50
Severe coronary artery disease 28 56
Smoking 16 32
Diabetes mellitus 11 22
Severe chronic obstructive pulmonary disease 3 6
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artery–jugular vein fistula, retrograde flow in the ICA is
ascertained with fluoroscopy by injecting a small amount of
contrast in the CCA and immediately opening the fistula,
observing contrast flow from the ICA into the internal
jugular vein.
The first 6 CAS procedures were performed with 2
separate introducer sheaths in the CCA, 1 (5F) to occlude
the external with a 4-mm balloon and connect to the
jugular vein fistula, and a second 5F introducer sheath to
conduct the intervention. The last 44 procedures were
performed with a single CCA 8F introducer sheath. ECA
flow was occluded with a separate 4-mm balloon in the first
22 procedures. The last 28 procedures were performed
without ECA occlusion, with angiographic demonstration
of ICA flow reversal in all cases. Using hand injection,
digital angiography was performed in the lateral and
oblique planes to localize and quantitate the degree of ICA
stenosis. With flow reversal in place, a 0.014-inch guide
wire (Platinum Plus, ST, 0.014-180 cm; Boston Scientific)
in a 4F 40-cm long Berenstein catheter (Angiodynamics)
was introduced through the CCA sheath for selective cross-
ing of the ICA stenosis. The tip of the guide wire was
advanced to a position just proximal to the carotid siphon.
Predilation of the lesion was performed in 28 patients
with balloons 3 or 4 mm in diameter. Self-expandable
stents 10  24 mm, 10  37 mm, 8  29 mm, or 8  36
mm (Biliary Wallstent, Monorail stent; Boston Scientific)
were used. Post-stent dilatation was performed for 5 to 10
seconds in all cases, with 5-mm  2-cm, 5.5-mm  2-cm,
or 6-mm 2-cm monorail balloon catheters (Ultra-soft SV
Monorail balloon catheter; Boston Scientific) inflated to 8
atm.
Completion carotid angiography was performed in all
patients to assess technical results and the presence of distal
spasm. Intra-arterial papaverine solution (1 mg/mL) was
selectively used to treat residual carotid spasm. After re-
moval of the sheaths the vessel access sites were closed with
5-0 or 6-0 polypropylene sutures, and the wound was
closed with absorbable sutures. After the procedure all
patients were observed in the recovery room for 6 hours,
then transferred to a floor or telemetry bed. Clopidogrel
was continued at 75 mg/day orally for at least 1 month,
and aspirin was continued indefinitely. One month after the
procedure, physical examination and carotid duplex scan-
ning were repeated in all patients.
Technical failure was defined as inability to access or
cross the lesion, or post-stenting residual stenosis equal to
or greater than 30%. Changes in intra-procedural mental
status were categorized as none, decreased, or unrespon-
sive. TIA was defined as a focal hemispheric deficit that
resolved within 24 hours. A focal deficit lasting more than
24 hours was defined as stroke. Recurrent or residual
in-stent stenosis was defined as more than 50% diameter
reduction as determined with duplex ultrasound scanning.
Outpatient follow-up was conducted at 1, 3, 6, and 12
months after surgery.RESULTS
All CAS procedures were completed successfully. No
significant residual stenosis occurred, and the ECA re-
mained patent in all patients. In 1 patient with a symptom-
atic, highly stenotic recurrent lesion diagnosed with ultra-
sound a few weeks earlier the ICA was found to be occluded
at surgery. The occlusion was crossed, and after ascertain-
ing wide patency of the distal, cervical ICA, it was stented
with excellent anatomic resolution of the stenosis, and
without complications.
Distal ICA spasm after CAS was noted in 6 patients
(12%), and resolved with papaverine solution injection in 5
patients and with additional balloon dilation in 1 patient.
Mean duration of the procedure was 66 minutes (range,
27-180 minutes), and mean ICA flow reversal time was
21.4 minutes (range, 9-50 minutes).
Early in the experience there was 1 postoperative ipsi-
lateral hemispheric TIA with upper extremity hemiparesis
and aphasia, which resolved within 3 hours of the proce-
dure. Flow reversal was not effectively established in this
patient, because of difficulty in placing the second intro-
ducer sheath in a small CCA. One intraoperative contralat-
eral hemispheric TIA occurred in a patient with contralat-
eral ICA occlusion, which resolved immediately after re-
establishment of antegrade flow. One patient complained
of severe eye pain without visual disturbance during the
procedure, but no visual field loss was found at postopera-
tive examination.
Among 27 patients who received local anesthetic for
the procedure, CCA occlusion was not tolerated in 1
patient (3.7%) with recurrent stenosis, contralateral ICA
occlusion, and contralateral stroke. This patient underwent
the procedure without protection and without complica-
tions. Transient mental status changes also occurred in
another patient with contralateral ICA occlusion and pre-
vious contralateral hemispheric stroke. This patient became
unresponsive at the end of the procedure, but recovered
immediately on re-establishment of antegrade carotid flow.
The remaining 5 patients with contralateral ICA occlusion
(4 patients under local anesthesia, 1 under general anesthe-
sia) tolerated the procedure well, without complications.
In response to ICA balloon dilation we observed bra-
dycardia or hypotension in 16 patients (32%). This vagal
response was mild in 14 patients, and did not require
treatment. In the other 2 patients intravenous drug admin-
istration was necessary. One of these patients sustained
severe hypotension, which responded to intravenous ad-
ministration of ephedrine, and the other patient sustained
asystole, immediately recovering pulse and pressure after a
precordial thump and atropine injection. Subsequently a
pacemaker was implanted in this patient. Paradoxically, 2
patients sustained a hypertensive response to ICA balloon
dilation, one of whom required intravenous treatment.
Mild pain was noted during ICA balloon dilation in some
patients, but severe neck pain was encountered in 2
patients, which required immediate angioplasty balloon
deflation.
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bral injection of papaverine solution in excessive concentra-
tion (30 mg/mL rather than 1 mg/mL) to resolve residual
ICA spasm after antegrade ICA flow was re-established.
This patient was given intravenous benzodiazepine agents,
and a endotracheal tube was placed, which subsequently
was removed within 30 minutes without sequelae.
During the first 12 procedures there were 3 minor
distal CCA dissections, which resolved after stent place-
ment, and 1 major CCA dissection, which required repair
with an interposition graft after stenting was completed.
Neck wound hematoma occurred in 2 patients, but only 1
required surgical drainage, although it did not delay dis-
charge from the hospital the day after surgery.
All patients were discharged from the hospital within 2
days of the procedure. There were no deaths or strokes at
30 days after surgery. During follow-up at 1 to 12 months
(mean, 7 months) all patients remained neurologically un-
changed, and carotid ultrasound scanning revealed that 49
carotid stents were patent without residual or recurrent
stenosis, and 1 carotid stent was occluded at 1 month after
the procedure.
DISCUSSION
Cerebral embolization is currently considered the ma-
jor risk associated with CAS. It has been well documented
that cerebral embolization occurs during all technical ma-
neuvers required for CAS,2 and that large numbers of
embolic particles are detected with transcranial Doppler
scanning of the middle cerebral artery during these proce-
dures.1,3 Because the embolic signals detected during CAS
are uncommonly associated with a clinically apparent neu-
rologic event, the significance of periprocedural emboliza-
tion during CAS is not well understood. A recent prospec-
tive study of 72 patients undergoing CAS without
protection revealed a 15% incidence of new ipsilateral brain
infarcts detected with postoperative magnetic resonance
imaging, 7% of which were clinically apparent neurologic
events.19 In another recent study of 70 unprotected CAS
procedures, 29% of the patients demonstrated new ipsilat-
eral hemispheric infarcts at magnetic resonance imaging,
and 9% had new contralateral hemispheric lesions, but only
1.4% were clinically evident.20 The latter observation sug-
gests that embolization also commonly occurs to the un-
treated carotid territory, possibly secondary to arch instru-
mentation or crossover migration of embolic particles.
Regardless of the immediate clinical significance of the
embolic phenomena, these findings reveal a strong associ-
ation between brain infarction and periprocedural emboli-
zation during CAS. Therefore embolization during CAS is
not an inconsequential phenomenon, and every effort
should be made to prevent it.
Distal protection devices reduce intraprocedural embo-
lization during CAS, but by no means eliminate it com-
pletely.9-11,21,22 Establishing ICA flow reversal before
crossing the ICA lesion during CAS is a major advantage of
the Parodi antiembolic system. In addition, the Parodi
transfemoral flow reversal catheter is the only cerebralprotection system that has shown rather complete elimina-
tion of intraprocedural embolization in vitro and in pa-
tients.14,16 For that reason, we incorporated ICA flow
reversal in our procedure, and enhanced ICA flow reversal
by using a larger caliber, shorter arteriovenous communi-
cation from the CCA to the jugular vein. Because of the low
resistance of our arteriovenous communication, our tech-
nique does not require occlusion of ECA flow to reverse
flow in the ICA. Therefore our technique eliminates a
technical step necessary to occlude the ECA with a balloon,
required with the transfemoral system developed by Parodi.
Our initial experience is extremely encouraging be-
cause of the absence of perioperative strokes, similar to the
initial clinical experience with the Parodi system,16 and
compares favorably with the results of CAS series using
dista protection devices with filters and balloons.7,12,23-25
The learning curve of our experience with this technique
was associated with CCA access complications. During our
first 12 cases we experienced 4 CCA dissections, 1 of which
required surgical repair of the CCA. Three of these dissec-
tions occurred during the first 6 procedures, which were
performed with 2 CCA introducers sheaths. After switch-
ing to a single 8F introducer sheath we experienced only 1
minor CCA dissection, which resolved after stent place-
ment. It should be noted that we did not have any ICA
dissections in our experience. Although we did not find any
cases in which CCA cannulation was not posible, preoper-
ative evaluation of the CCA with duplex scanning is advis-
able to identify the presence of calcification or other disease
that would make the transcervical approach ill-advised.
Stenotic or calcified CCAs are a contraindication for the
procedure, and in patients with very low bifurcations the
procedure may be difficult, and the transfemoral route is
probably a safer approach. The need for a cervical cutdown
of the CCA could be considered a drawback of our tech-
nique. However, we have had only had 1 wound hematoma
that required surgical drainage under local anesthesia. It is
necessary to consider that these 50 patients represent our
initial experience with a newly devised procedure and that
with increasing experience and by using specifically de-
signed devices for the procedure a lower complication rate
can be expected. Our initial experience suggests that tran-
scervical CAS may be accomplished with a low stroke or
complication rate, comparable to other approaches. Our
follow-up data, however, are limited, and do not allow
analysis of the long-term incidence of recurrent stenosis
and freedom from stroke.
Carotid intervention through the femoral approach
carries additional risks of retroperitoneal or groin bleeding
or hematoma, iliofemoral arterial dissection, pseudoaneu-
rysm formation, arteriovenous fistula, nerve injury, arterial
thrombosis, extremity and visceral embolization, and ipsi-
lateral or contralateral cerebral hemispheric embolization.
The incidence of femoral access-related complications dur-
ing CAS is not clearly reported in the literature. We can
extrapolate from the coronary intervention experience from
the last decade that a 5% to 15% femoral access complica-
tion rate may be expected, by no means an insignificant
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possible that with increasing experience the overall morbid-
ity with transcervical CCA may be lower than that with the
transfemoral approach. An additional benefit of the tran-
scervical approach is that it enables immediate ambulation
of the patient after the procedure, facilitating performance
on an ambulatory basis.
Neurologic tolerance to ICA flow reversal was excellent
in 96% of our patients, a rate similar to that with protection
using ICA flow reversal through a femoral catheter,16 but
perhaps better than the 85% to 95% tolerance reported
during protection with distal balloon occlusion devic-
es.21,25 Carotid flow reversal was tolerated in all 43 patients
with a patent contralateral ICA. It was not tolerated, how-
ever, in 2 of 7 patients (29%) with an occluded contralateral
ICA. One of these 2 patients had immediate intolerance to
CCA occlusion, and underwent stenting without protec-
tion, and the other patient was unresponsive at completion
of the procedure, but recovered immediately on re-estab-
lishment of antegrade ICA flow. A similar 19% intolerance
rate was found by Lawrence et al27 in 26 patients with
contralateral ICA occlusion undergoing carotid endarter-
ectomy under local anesthesia.
Ipsilateral brain perfusion during ICA flow reversal
depends on hemispheric resistance to collateral flow from
the posterior circulation, the contralateral hemisphere, and
pial vessels, and preservation of ipsilateral hemispheric ox-
ygen saturation with this mechanism has been documented
during ICA flow reversal in a subset of these patients.18
Inasmuch as cerebral perfusion pressure and mean systemic
arterial pressure are linearly related, increasing mean sys-
temic arterial pressure with pharmacologic agents would
possibly further decrease the rate of neurologic intolerance
to ICA flow reversal.28,29 With increasing experience with
transcervical CAS the duration of the procedure and of
carotid flow reversal should be significantly shortened, and
improved neurologic tolerance can be expected. Neverthe-
less, our initial experience suggests that patients with con-
tralateral ICA occlusion are more likely to not tolerate flow
reversal, and a different method of cerebral protection
should be considered in these patients. The use of transcra-
nial Doppler monitoring of the middle cerebral artery flow
characteristics during the procedure may help to predict
which patients are more likely to tolerate cerebral flow
reversal.
The vagal response to ICA balloon inflation during
CAS is unrelated to the use of protection devices. In our
experience, 16 patients (32%) sustained a vagal response,
but only 2 of these patients (12%) required treatment. The
report by Leisch et al30 corroborates our experience, find-
ing that 40% of patients undergoing CAS reacted to carotid
body stimulation during balloon inflation, most commonly
with short-term hypotension, but without clinical symp-
toms and not associated with periprocedural cerebral com-
plications. Of interest, hypertension developed in 2 patients
in our series in response to ICA balloon inflation, and 1 of
these patients required intravenous drug administration.Distal protection with filtering devices has the advan-
tage of not interrupting antegrade carotid flow during
CAS. However, this benefit may be offset by a 2% to 6% rate
of filter placement failure,26,27 risk for lesion crossing be-
fore filter protection is in place, and intrinsic risks and
limitations of filters in capturing embolic debris.8 Trans-
femoral access for CAS may not be feasible in patients with
severe occlusive disease of the aorta and iliofemoral arteries.
CCA cannulation may be impossible in patients with tor-
tuous supra-aortic trunks or unfavorable arch anatomy, and
aortic instrumentation may be ill-advised in patients with
emboligenic aortic plaque. In addition, distal protection
device deployment failure occasionally occurs. It is difficult
to quantitate the individual incidence of these conditions,
because they typically lead to aborted procedures that
mostly are unreported. The combined incidence of all of
these problems could amount to a significant rate of trans-
femoral cerebral protection failure on an intention-to-use
basis. When CAS is indicated in patients with unfavorable
anatomy or emboligenic plaque, the transcervical approach
may be a technically easier and safer option.
Finally, the inclusion of cerebral protection devices
significantly increases the cost of CAS, an already techno-
logically expensive intervention, whereas the transcervical
approach with ICA flow reversal has the advantage of
providing cerebral protection without the additional cost of
protection devices.
In summary, our initial experience suggests that tran-
scervical CAS with ICA flow reversal for cerebral protection
can be performed safely with a low neurologic complication
rate. The procedure is well tolerated with local anesthesia in
most patients. The procedure is feasible in most situations
where the transfemoral route is impossible or contraindi-
cated. It overcomes the limitations of distal protection
systems, and eliminates their cost. Thus transcervical CAS
with ICA flow reversal is a safe and effective alternative in
patients in whom carotid stenting is indicated.
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Submitted May 3, 2004; accepted Jun 22, 2004.DISCUSSIONDr Robert W. Hobson (Newark, NJ). I have questions in 3
or 4 areas. We have restricted performance of these procedures to
transfemoral methods. Only 2% of our 194 consecutive procedures
were done by direct cervical carotid exposure and cannulation
when femoral arterial access was compromised. We have not ob-
served your predicted 5% to 15% local complication rate with
femoral cannulations.
My first question is this: What has your complication rate been
with other transfemoral endovascular procedures? Do you have a
group of carotid artery stent procedures using conventional trans-
femoral cannulations for comparison so that we get some appreci-
ation of the differences?
Secondly, nearly half of your procedures were performed
under general anesthesia with the indicated incision. How do you
select patients for the transcarotid procedure as opposed to simply
going ahead with a carotid endarterectomy? Should this procedure
be reserved for high-risk patients, who really constituted 80% of
your sample?
Thirdly, can you provide us a little additional detail about the
flow reversal technique? You injected contrast to confirm reversal
and, in the manuscript, described a rationale for avoiding balloon
occlusion of the external carotid. If blood were aspirated through
the common carotid arterial sheath during and after carotid artery
stenting, would you also predict flow reversal? And if so, could youavoid the use of the internal jugular fistula altogether, thereby
making it, perhaps, a little bit easier to perform.
You reported an 8% incidence of common carotid artery
dissection. Now, presumably the dissection occurs at the point
your sheath goes into the artery, so you can’t cover that with the
stent. So could you describe a little bit more about those dissec-
tions and how you might prevent them?
Finally, you had a 32% incidence of hypotension and brady-
cardia. Give us a little sense of your clinical protocol. Do the
patients get antihypertensives on the morning of the procedure?
Do you use atropine routinely?
You had one asystole, which must have been a difficult time for
you in the operating room. And do you always, therefore, have a
transvenous pacemaker available?
I urge you to continue to collect clinical data on transcervical
carotid artery stenting. In my opinion, it will not replace trans-
femoral carotid artery stenting, but it is a method that all vascular
surgeons should acquire for cases with compromised femoral ac-
cess.
Dr Enrique Criado. I cannot tell you our current femoral
access complication rate, but it is my impression that is rather low.
The complication rate I quoted is from the cardiology literature for
coronary interventional procedures. It is perhaps early to know
what is going to be the femoral complication rate specifically for
carotid intervention.
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high-risk patients, no question about it. I would admit, however,
that a number of our patients were not necessarily high-risk pa-
tients.
In regard to the reversal of flow in the carotid artery, I believe
that the main advantage of our technique is that it provides a
high-flow fistula that washes out all debris throughout the proce-
dure from the very beginning. I think we need to do much more
work, as you suggested, including intraoperative studies with
transcranial Doppler to see what happens in the middle cerebral
artery with the flow reversal and what is the incidence of HITS
during the procedure. Dr Parodi, however, has documented that
the number of HITS during this procedure, at least those done
transfemorally with another balloon in the external carotid artery,
is rather small if not inexistent.
In terms of the bradycardiac events in response to balloon
inflation in the internal carotid artery, we do not have a specific
protocol owing to the tendency of the responses to be rather mild.
We see a number of bradycardias and mild hypotensions, but most
of them have been asymptomatic and have not required treatment.
We had 1 episode of asystole that responded immediately to
atropine and to a precordial thump. We do not have temporary
pacemakers available, but I think they should perhaps be in the
operating room; however, we certainly have drugs available to be
injected intravenously.
Dr Maciej L. Dryjski (Buffalo, NY). Could you explain why
you chose this approach versus the femoral approach? Do these
patients have a problem with the femoral arteries, or was this just
because you found it easier? And the second question is that an 8%
incidence of carotid dissection seems to be extremely high, so do
you still plan to do these procedures?
Dr Criado. Well, first of all I stated that the rationale for the
transcervical approach is to avoid the limitations of other protec-
tion devices, to provide what we believe a better, perhaps superior
way of inverting flow in the internal carotid artery to provide the
best protection during the manipulation of the lesion in internal
carotid artery. There was nothing wrong, that I can recall, with the
femoral pulses in most of these patients.
In regard to the dissections, we had 4 during the first 12 cases.
And at the beginning of our experience, we were using 2 introduc-
ers in the CCA, 1 to occlude the external and the other to actually
conduct the procedure. We very soon found out that that was not
a good idea, and we switched to a single introducer sheath, which
made the procedure easier.
All dissections, actually, were not at the entry site, but were
more distal, probably made by the introducer sheath’s tip. Carotid
access is probably the riskier, more difficult part of the procedure.
Once we switched to the 4F micropuncture kit and a single CCA
sheath, we have not had any problems. However, the potential
problems are there. I would like to remind you that we also see a
good number of dissections in the femoral and iliac arteries from
interventional access.
I think, considering that this is a very preliminary experience,
the results are quite encouraging. And unless somebody else proves
to me that protection can be provided better by other means, we
should continue to do it.
Dr John Blebea (Philadelphia, Pa). Your approach certainly
has some advantages, not the least of which is that it still maintains
the procedure within the purview of vascular surgeons. Have you
measured the actual flow within the loop? Because I can see on the
angiogram how you have reversal of flow, but, once you use the
same introducer sheath for your stent and the balloon, there is no
question that the backflow through that sheath is going to be
decreased. So during the actual procedure, do you, in fact, have
continued reversal of flow, and is that flow going to be sufficient
and is the lumen large enough so if you get larger particulate
matter? In fact, does it have room to reverse and go through your
arteriovenous fistula instead of just staying outside the sheath and
as soon as you pull out it’s still embolized distally?Dr Criado. First of all, we obviously don’t have a way of
measuring intraprocedural flow. But if you look at the caliber of the
size of the sheaths we use, which are 8Fs, and if you put one of
these Monorail balloons inside, or even the Monorail stent, you
will see that the Monorail balloon or stent occupies actually a very
small part of the cross-sectional area of the sheath. So there’s
actually plenty of room for reverse flow around our devices.
This was one of the limitations, or is one of the limitations of
the PAES, of the Parodi Antiembolic System—it is not only smaller
in size (a 7F sheath) but it is so long that the resistance is higher.
I agree with you, but throughout the procedure when injec-
tions of dye are often done by hand, with very small injections to
ascertain position and whatnot, every single time you see the flow
upon reestablishment of the fistula, the flow is automatically re-
versed. Flow reversal, however, is proportional to the gradient
from your back stem pressure, as you can imagine, and your
internal jugular vein pressure. But in general, sometimes it’s faster,
sometimes slower, depending on that back stem pressure. But it is
always there. We have not seen a single case with back stem
pressure, where the flow was not reversed. Occasionally, however,
I admit, it is very stagnant when the carotid lesion is very tight. And
after you actually open up the lesion with the stent or the balloon,
then you see that the flow reversal is actually much faster.
Dr John J. Ricotta (Stony Brook, NY). I think you should
comment a little bit on the contralateral occlusion patients and the
patients who may or may not tolerate flow reversal.
Dr Criado. In the whole series, there were actually 7 patients
with contralateral ICA occlusions, 6 of which were done under
local. Of those 6 under local, where we could actually monitor the
neurologic status throughout the procedure, 4 tolerated the pro-
cedure without any problems, which was better than I expected.
This is actually in line with what happens with carotid occlusion
during carotid endarterectomy, if you review the literature. Actu-
ally, there is a nice article by Lawrence documenting that grade of
tolerance to carotid occlusion.
One patient did not tolerate common carotid occlusion at all,
from the very beginning. We would cinch down the CCA and the
patient would just try to get off the table. It was very dramatic. So
that patient had recurrent stenosis. We conducted the procedure
without protection, because I believe that recurrent stenosis for
endarterectomy perhaps has a lower embolic rate.
And the other patient did well throughout the procedure. And
when we were pretty much done, and were just about to dilate the
stent following the completion, he became unresponsive. And a
few seconds later, we opened up, we reestablished antegrade flow
towards the brain, and he recovered right away.
The same thing happened with a contralateral TIA, in a patient
with a previous stroke. It was a motor TIA and the patient had had
similar symptoms when he had the stroke months before. Upon
re-establishment of antegrade flow, the motor deficit actually
recovered and disappeared.
So that has been my experience. However, having said that, I
think you have to very careful and very cautious when you do this
procedure in patients with contralateral occlusion. Dr Parodi sug-
gests, and we may try this, that if you increase the mean systemic
arterial pressure with phenylephrine, or other drugs perhaps, the
threshold for tolerance to flow reverse in patients with contralateral
occlusion may go higher and some of these patients who might not
be able to tolerate the procedure under normal circumstances may
do so with a little higher pressure. I’m not sure I’m willing to try
that because of the pharmacologic intervention. Perhaps, those
patients are better served by other means. I’m not sure.
Dr Michael A. Golden (Philadelphia, Pa). I did have a
question about the distance between the tip of your sheath in the
carotid and the Rumel tourniquet. It seems to me that you have
sort of a cul-de-sac dead space there that would potentially allow
debris to not be evacuated by the tip of the sheath, since I assume
the tip of the sheath has to be in the artery enough that the sheath
doesn’t end up coming out while you’re moving things back and
forth.
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actual introducer sheath to limit introduction of the sheath to 3 cm
into the carotid. We don’t want to have the sheath all the way up
because it could create an additional injury. That could actually be
further shortened. You have to bear in mind, these are commer-
cially available devices that are used for other purposes. We’re now
working to design a catheter that is a little more specific for the
neck and create a gadget that would make the procedure safer and
easier.
But you’re right, you’re potentially creating throughout the
procedure a small area of stagnant flow where the debris could
accumulate. But, as long as the flow is reversed throughout the
procedure by the venturi effect, the debris is preferentially going to
follow the path of least resistance with the flow, which would be
into the sheath and into the internal jugular.
Dr Sal Cuadra (Newark, NJ). You mentioned the high
proportion of patients needing general anesthesia. I’m not sure if
you gave detail. Were these patients who had to be converted to
general anesthesia because there was a problem intraoperatively, or
were these just started as general anesthesia from the beginning of
the case by surgeon preference?
Dr Criado. It happens in all initial experiences. We try to be as
cautious and careful at the beginning. And our decision, when we
started doing these procedures, which were started overseas with
my colleagues, is we just had to do it under general first. After more
experience and developing the technique a little better, we felt
comfortable in initiating the cases under local. Now, it’s the
opposite. Now, it’s only occasionally that the patients either re-
quest or, perhaps, need to be converted to general. So I don’t think
there’s any reason to do this under general.
Dr Linda Harris (Buffalo, New York). Have you considered
evaluating these patients with transcranial Doppler (TCD) scans to
see whether or not there are any distal emboli? And also, are you
concerned at all about pulmonary emboli or paradoxical emboli
with your technique?
Dr Criado. Absolutely. My chairman is very supportive, and
I’m hopeful that he will buy us a TCD soon so we can actually
document this. We already have a TCD scheduled for a case on
Monday. But Dr Parodi has looked at a TCD of these patientsthrough the femoral approach and the low incidence of HITs is
remarkable.
In regard to the paradoxical embolization, that’s an excellent
point. Some of these patients may have a right-to-left communi-
cation and there’s always a potential for peripheral or cerebral
embolization. That is fixable with a filter. The reason we did not
use a filter initially was that the only filter we had available was the
commonly available blood filter, which may actually increase the
resistance of the fistula to a point where the flow is not efficient
enough. But we’re willing to use a filter when we find one which
does not limit flow reversal, although I think that the potential for
paradoxical embolization is rather low.
Dr Michel Makaroun (Pittsburgh, Pa). With so few long-
term follow-up results of how the stent is going to behave in the
carotid artery, how would you convince a surgical audience and
their patients that the incision you are making is any different or
any less stressful than a carotid endarterectomy, especially since the
surgeons are having a hard time buying that the puncture of the
femoral artery might be a little bit less stressful or involved than an
incision in the neck and the president of the Society does about a
2.0 to 2.5-cm incision for essentially all of the carotid endarterec-
tomies. So how do we justify this going into the neck and making
the incision just to put a stent, when you can do with about the
same incision the carotid endarterectomy?
Dr Criado. Well, I’m not trying to justify anything. I think
that it’s rather obvious, and I think this is a very, very small, very
quick common carotid dissection. By no means is it equal to a
full-fledged carotid endarterectomy.
You could argue that carotid endarterectomy is associated
with peripheral nerve injury. We still have a few of those. But
obviously, you do not have that complication with this approach.
I do not agree that this kind of cutdown is equivalent to a
carotid endarterectomy. The main thrust of this is to actually try to
investigate a procedure which may produce the fewest number of
emboli during carotid artery stenting. That’s the main goal of this
procedure. I’m not trying to justify the nonuse of the femoral or
any other approaches. But I think we need more data and perhaps,
eventually, some comparative studies to see what comes out on
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